SynthesisBMC endocrine disorders2026
Associations between the triglyceride‒glucose index and the odds of low muscle mass and sarcopenia: a systematic review and meta-analysis.
Synthesis in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia, the age-related loss of muscle mass and function, is a public health concern linked to insulin resistance (IR). The triglyceride‒glucose (TyG) index, a marker of IR, may reflect a decrease in muscle health.
methodsThis meta-analysis, which adhered to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, reviewed studies from electronic databases investigating the association between the TyG index and low muscle mass or sarcopenia. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated via a random effects model.
resultsTwenty cross-sectional studies involving 521,778 participants were included. A higher TyG index was associated with higher odds of low muscle mass (OR = 1.28; 95% CI: 1.10–1.50) and sarcopenia (OR = 1.63; 95% CI: 1.29–2.07). Dose‒response analysis revealed that for every 1-unit increase in the TyG index, the odds of low muscle mass were 1.79 times higher (OR = 1.79; 95% CI: 1.60–2.00).
conclusionThe TyG index is linked to higher odds of low muscle mass and sarcopenia, highlighting its potential as a screening tool. However, due to the cross-sectional design of the included studies, causal relationships cannot be inferred. Longitudinal studies are needed to establish causality. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.